Abstract

The COVID-19 pandemic has catalyzed significant advances in stem cell research, particularly in the investigation of mesenchymal stem cells (MSCs) as potential therapeutic agents for both acute and long-term sequelae of SARS-CoV-2 infection. Owing to their immunomodulatory, anti-inflammatory, regenerative, and tissue-repair properties, MSCs have emerged as promising candidates for attenuating cytokine dysregulation, promoting pulmonary regeneration, and mitigating manifestations of long COVID. This review examines the therapeutic potential of MSC-based interventions for COVID-19-associated lung injury and persistent post-COVID complications, drawing upon evidence from preclinical studies, animal models, and clinical investigations. Current findings suggest that MSCs may contribute to immune homeostasis, reduction of hyperinflammation, enhancement of alveolar repair, and restoration of pulmonary function; however, substantial challenges remain, including scalable manufacturing, cell product standardization, quality control, long-term safety assessment, and ethical considerations surrounding stem cell applications. Although preliminary data indicate potential clinical benefits, further mechanistic studies and well-designed, adequately powered randomized clinical trials are required to establish the efficacy, safety, optimal dosing strategies, and therapeutic mechanisms of MSC-based therapies. The development of robust regulatory frameworks and ethical guidelines will be essential for facilitating the translation of regenerative medicine approaches from experimental settings to routine clinical practice. Equally important is ensuring equitable access to these emerging therapies, particularly for underserved populations, to prevent the widening of existing health disparities. Furthermore, long-term patient follow-up is necessary to monitor potential adverse outcomes, including tumorigenicity, immune-related complications, and other delayed effects, while evaluating the durability of therapeutic responses. Addressing these scientific, regulatory, manufacturing, and accessibility challenges will not only improve recovery outcomes for individuals affected by COVID-19 but may also advance the broader application of stem cell therapy and regenerative medicine for inflammatory disorders, chronic diseases, and future pandemic preparedness, ultimately contributing to improved global health equity.

Keywords

COVID-19, SARS-CoV-2, mesenchymal stem cells (MSCS), stem cell therapy, regenerative medicine, long covid, post-acute sequelae of covid-19 (PASC), cytokine storm, immunomodulation, lung injury, pulmonary regeneration, tissue repair, inflammation, clinical translation, cell therapy, health equity